Dilated cardiomyopathy (DCM) is a medical condition in which the heart’s ability to pump the blood is decreased because the heart’s main pumping chamber, the left ventricle, is enlarged, dilated, and weak. Dilated cardiomyopathy may affect the functioning of other organs such as kidney, liver, and lungs. The heart muscle begins to dilate, as a result of which the chamber area becomes dilated and enlarged, further spreading into the right ventricle and atria. The heart muscles do not contract normally, as the heart chambers dilate, and are no longer able to pump blood in the normal way. Moreover, heart becomes weak, which may lead to heart failure.
Request Free Sample Copy With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/514
Dilated cardiomyopathy can occur due to various reasons, such as uncontrolled blood pressure, viral infection, problem with the heart valve, and excessive amount of alcohol. There is no cure for DCM, doctor’s use congestive heart failure drugs to treat DCM. DCM occurs mainly in the age group of 20-60 years and rarely among children. Dilated cardiomyopathy can be diagnosed by normal chest X-ray and echocardiogram, as well as cardiac MRI. Implantable devices, such as pacemaker and defibrillator, are used to maintain the rhythmic function of the heart and to avoid the chances of cardiac arrest. According to the British Heart Foundation, around 25,000 pacemakers are implanted in the United Kingdom every year.
Increasing incidence/cases of congestive heart failure around the world is expected to boost the growth of the global dilated cardiomyopathy market during the forecast period. For instance, according to the American Heart Association, there were approximately 5.7 million cases of heart failure in the United States in 2016.
Moreover, continuous research for the development of novel drugs, such as Ixmyelocel-T and ARRY-797, is expected to propel growth of the global dilated cardiomyopathy market.
The global dilated cardiomyopathy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East and Africa.
Among regions, North America and Europe are expected to witness significant growth in the global dilated cardiomyopathy market, owing to the increase in cases of congestive heart failure and increasing prevalence of cardiovascular disease in these regions. For instance, according to the European Heart Network 2017 report, cardiovascular disease accounted for around 3.9 million deaths in Europe and over 1.8 million deaths in the Europe Union.
Moreover, Asia Pacific is expected to witness robust growth in the market due to the increasing demand for generic drugs and increasing prevalence of cardiovascular disease in the region.
Key players active in global dilated cardiomyopathy market are Pfizer Inc., Array BioPharma, Johnson & Johnson, AstraZeneca, Sanofi, and GlaxoSmithKline Plc., among others.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/514
In August 2019, MyoKardia announced the launch of 2nd Annual MyoSeeds Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and precision heart disease treatment.
In March 2019, DCM Foundation launched a website, www.dcmfoundation.org, to promote awareness of DCM and to educate patients and their families on the symptoms, stages, and management of this heart condition.
In October 2018, MyoKardia and 23andMe teamed up to create a patient community to advance research into hypertrophic cardiomyopathy (HCM), a progressive and frequently debilitating disease characterized by excessive contractility of the heart.
In March 2017, Phosphorus announced the launch of advanced genetic tests for the diagnosis of dilated cardiomyopathy. The tests will help affected patients and their family members guide disease management to prevent severe cardiac events, such as heart attack or sudden death.
- Blood thinning medications
- Beta Blockers
- Cardiac glycosides
- Angiotensin-Converting Enzyme (ACE) inhibitors
- Angiotensin II receptor blockers
- Implantable Devices
- Heart Pumps
- Retails Pharmacies
- Mail order Pharmacies
- Online pharmacies
- Hospital Pharmacies
- North America
- Latin America
- Middle East
𝐂𝐡𝐫𝐢𝐬𝐭𝐦𝐚𝐬 𝐒𝐚𝐥𝐞 𝐈𝐬 𝐋𝐢𝐯𝐞
𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐎 𝐀𝐯𝐚𝐢𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐅𝐫𝐨𝐦 𝟐𝟓-𝟑𝟎% 𝐓𝐢𝐥𝐥 𝟑𝟏-𝐃𝐞𝐜-𝟐𝟎𝟐𝟏
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/514
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027